Amicus Therapeutics (FOLD) to Release Earnings on Thursday

Amicus Therapeutics (NASDAQ:FOLD - Get Free Report) will likely be issuing its Q1 2025 quarterly earnings data before the market opens on Thursday, May 1st. Analysts expect the company to announce earnings of $0.08 per share and revenue of $136.32 million for the quarter.

Amicus Therapeutics Trading Up 2.0 %

Shares of Amicus Therapeutics stock traded up $0.15 on Tuesday, reaching $7.54. The company had a trading volume of 794,892 shares, compared to its average volume of 2,622,955. The firm's 50 day moving average price is $8.11 and its two-hundred day moving average price is $9.37. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39. Amicus Therapeutics has a 52-week low of $6.20 and a 52-week high of $12.65. The firm has a market cap of $2.32 billion, a PE ratio of -41.83, a PEG ratio of 1.51 and a beta of 0.79.

Analyst Ratings Changes

A number of research analysts have commented on FOLD shares. Wells Fargo & Company decreased their price target on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research note on Thursday, February 20th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $21.00 target price on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. StockNews.com cut shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research report on Thursday, February 20th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $16.75.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.